AGARWAL SUNIL
SEC insider (Form 3/4/5 filer). CIK 0001616640. Director at Astria Therapeutics, Inc. (ATXS) and 1 other issuer. 4 reported Form 4/5 transactions since Sep 2024; latest on Jan 23, 2026. Located in BOSTON, MA.
Companies AGARWAL SUNIL has filed insider reports for
- Astria Therapeutics, Inc. (ATXS): Director
- ARVINAS, INC. (ARVN): Director
AGARWAL SUNIL
CIK: 0001616640
Transaction Breakdown
Open Market Buys (P)0 (0.0%)
High conviction signal
Open Market Sales (S)0 (0.0%)
Position reduction
Option Exercises (M)0 (0.0%)
Derivative conversions
Awards (A)2 (50.0%)
Compensation grants
Other (G, F, J, C, D, …)2 (50.0%)
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (4 total)
- Jan 23, 2026ATXS
Astria Therapeutics, Inc.
DispositionDirectStock Option (Right to Buy)
28.2K shares- - Jan 23, 2026ATXS
Astria Therapeutics, Inc.
DispositionDirectStock Option (Right to Buy)
26.6K shares- - Jun 25, 2025ARVN
ARVINAS, INC.
AwardDirect16K shares- - Jun 11, 2025ATXS
Astria Therapeutics, Inc.
AwardDirectStock Option (Right to Buy)
26.6K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jan 23, 2026 |  ATXS Astria Therapeutics, Inc. | Disposition Stock Option (Right to Buy) | 28,200 | - | - | Direct |
| Jan 23, 2026 | ATXS Astria Therapeutics, Inc. | Disposition Stock Option (Right to Buy) | 26,550 | - | - | Direct |
| Jun 25, 2025 |  ARVN ARVINAS, INC. | Award | 16,025 | - | - | Direct |
| Jun 11, 2025 | ATXS Astria Therapeutics, Inc. | Award Stock Option (Right to Buy) | 26,550 | - | - | Direct |
1-4 of 4 transactions